Zealand Pharma AS (fra:22Z) Share Price

Company Profile

Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNK
T: +45 88773600
E: [email protected]
https://www.zealandpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
544

Recommended

We think this improves Nvidia’s position within the open-source community.

Brian Colello, CPA | 03 September 2026

Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.

Tom Lauricella | 03 September 2026

Elevated copper prices raise valuation questions.

Tyger Fitzpatrick | 02 September 2026

Index	Last price	Change	% Change
All Ordinaries	9,196.00	54.60	-0.59%
CAC 40	8,278.77	7.63	-0.09%
DAX 40	26,046.40	43.08	0.17%
Dow JONES (US)	53,414.25	271.86	-0.51%
FTSE 100	10,831.09	0.43	-0.00%
HKSE	25,650.87	437.56	1.74%
NASDAQ	26,506.99	77.07	-0.29%
Nikkei 225	65,020.94	806.46	1.26%
NZX 50 Index	13,974.18	128.00	0.92%
S&P 500	7,718.60	29.11	-0.38%
S&P/ASX 200	9,005.90	64.30	-0.71%
SSE Composite Index	3,930.12	11.97	-0.30%